Neuropathy Assessments & Therapies

At Diabetes Testing Centers™  (DTC), we recognize that diabetes affects more than just blood sugar—it impacts the entire nervous system. Our Neuropathy & Cognition Program™ offers comprehensive screening and management solutions, integrating advanced neuropathy testing (e.g., small and large fiber assessments) with cognitive evaluations to detect and address these interconnected conditions early. This program empowers providers with reimbursable, data-driven insights to halt progression, improve patient outcomes, and optimize RAF scores through HCC v28 coding (e.g., HCC 19 for diabetes, HCC 18 for neuropathy, and HCC 52 for cognitive impairment).

Neuropathy + Cognitive Risk. Neurologically, neuropathy and cognitive decline in diabetes share overlapping pathways driven by hyperglycemia-induced nerve damage. In diabetic neuropathy, elevated glucose levels cause oxidative stress, inflammation, and microvascular injury, leading to axon degeneration and demyelination in peripheral nerves. This disrupts sensory and motor functions, resulting in symptoms like neuropathy pain and balance issues. Similarly, in the brain, chronic hyperglycemia impairs insulin signaling (brain insulin resistance), promoting amyloid-beta accumulation and tau hyperphosphorylation—hallmarks of Alzheimer's disease pathology. These processes are interconnected through systemic inflammation (e.g., elevated cytokines) and vascular dysfunction, where damaged blood vessels reduce nutrient delivery to both peripheral nerves and cerebral regions like the hippocampus (memory center).

Simultaneously, diabetes complications accelerate shared mechanisms such as advanced glycation end-products (AGEs), which stiffen tissues and promote neuroinflammation, affecting peripheral nerves (causing neuropathy) and central neurons (leading to cognitive decline). Autonomic neuropathy may further exacerbate brain changes by altering cerebral blood flow, while cognitive impairment can worsen neuropathy management (e.g., poor adherence to foot care, increasing amputation risk). This bidirectional relationship means patients with diabetic peripheral neuropathy often exhibit early cognitive slowing, affecting domains like executive function and processing speed, potentially progressing to Alzheimer’s-like dementia.

Our program addresses this by combining neuropathy diagnostics with cognitive screenings, enabling early interventions such as biofeedback balance training and drug-free pain relief therapies to mitigate both conditions. Lastly, we include NutriNerve® by world-renowned Dr. Aaron Vinik, MD, PhD, as an ongoing all-natural antioxidant supplement for all nerves, representing the best that scientific thinking can offer for nerve health. Backed by his clinical studies on neuropathy and inclusion in his treatments, NutriNerve® represents the highest standard of scientific thinking in nutritional support for continued therapies as a monthly maintenance.

Clinically Supporting the Connection

Clinical studies consistently demonstrate a strong link between type 2 diabetes, diabetic neuropathy, and cognitive decline, underscoring the importance of integrated screening and early detection. A 2021 cross-sectional study of 104 type 2 diabetes patients found that the severity of diabetic peripheral neuropathy (DPN) was significantly negatively correlated with cognitive performance (r = -0.35, p < 0.01), particularly in memory and executive function, suggesting shared microvascular complications. Similarly, a 2021 meta-analysis of 1,200+ participants showed that individuals with type 2 diabetes and DPN had lower mean cognitive performance (standardized mean difference = -0.45, p < 0.001) compared to those without neuropathy, with deficits in attention, processing speed, and brain function.

Longitudinal evidence strengthens this connection. A 2021 study of 1,400 adults with type 2 diabetes revealed that diabetic neuropathy was associated with a 1.5-fold increased risk of cognitive impairment over 5 years (HR = 1.52, 95% CI 1.12–2.05), independent of age and glycemic control. Another 2024 cohort study of 500 diabetic patients reported worse cognition in neuropathy cases across memory and processing domains (p < 0.05), attributing this to chronic hyperglycemia, inflammation, and nerve damage. In a 2024 analysis, diabetic microvascular complications (including neuropathy) contributed to a 20–30% higher incidence of cognitive decline and depression (p < 0.01), highlighting the need for early cognitive screening in diabetes care.

These findings align with broader data: Patients with type 2 diabetes face a 1.5–2 times higher risk of Alzheimer’s disease, with neuropathy emerging as a key clinical marker (meta-analysis of 15 studies, RR = 1.6, 95% CI 1.2–2.1).

Diabetic Neuropathy Accounts for More Hospitalizations Than All Other Diabetic Complications Combined...

Aaron Vinik, MD, Ph.D., Endocrinologist, Diabetic Neuropathies, February 5, 2018